We are monitoring the impact of COVID-19 on APAC Active Pharmaceutical Ingredients Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 11470
Share on
Share on

APAC Active Pharmaceutical Ingredients Market Research Report – Segmented By Type of Manufacturing Process, Type of Synthesis, API Formulation, Application, Molecules and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) – Industry Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 11470
Pages: 100

APAC Active Pharmaceutical Ingredients Market Size (2021 to 2026)

As per our research report, the APAC Active Pharmaceutical Ingredients Market size is predicted to be growing at a significant CAGR of 10.24% during the forecast period.

The active pharmaceutical ingredients market in the APAC region is most likely to be driven by the Y-O-Y growth in the prevalence of chronic diseases, increasing adoption of biopharmaceuticals, and enhanced drug research and development activities. Furthermore, advancements in the manufacturing of active pharmaceutical ingredients, rising cardiovascular diseases and cancer in the APAC region, and changes in geopolitical situations are pushing the market growth. Diabetes, cardiovascular disease, asthma, arthritis, and chronic obstructive pulmonary disease have increased in the geriatric population in emerging countries such as India and China. Changes in lifestyle and dietary habits brought on by urban development will have an even more significant impact on market development.

On the other hand, favorable government policies for API development and increased government and private sector investment and funding for developing healthcare infrastructure in Asian countries fuel the regional market growth. Governments in developing countries such as India and China have developed plans and provided incentives to encourage API development. Aging weakens the immune system, making patients more vulnerable to infectious diseases.

Besides, deficiency of body functions raises the risk of contracting disorders such as CVD and diabetes. APIs are frequently used in the formulation of Antibody Drug Conjugates (ADCs). ADCs are essential and effective cancer therapy modalities used in conjunction with clinically active drugs and monoclonal antibodies; thus, the creation of cancer-specific APIs is expected to propel the API market even further.

Unfavorable drug pricing policies in Asian countries restrain the market growth. The high manufacturing cost of APIs is one of the significant challenges which market participants face. Furthermore, the development of these APIs requires substantial investments, which are unaffordable in underdeveloped nations. API chemical synthesis often involves expensive and uncommon building blocks and raw materials, raising API manufacturing costs much further.

Impact of COVID-19 on APAC Active Pharmaceutical Ingredients Market:

The World Health Organisation proclaimed COVID-19 a pandemic and issued specific guidelines for disease containment. Because of the widespread of novel coronaviruses, all regions, including APAC, have been put under lockdown. Many pharmaceutical and biopharmaceutical companies and start-ups are stepping forward to develop a COVID-19 treatment. The COVID-19 epidemic has prompted drug makers and distributors to concentrate their efforts on a massive patient population. The abrupt emergence had disrupted the Asian drug supply chain. The prevalence of chronic illnesses, on the other hand, has boosted demand for medications, which is projected to grow the active pharmaceutical ingredients market. The economic and social costs of pandemics have driven governments to create and mass-produce an effective coronavirus vaccine. As a result, rising funding and research for pharmaceutical product development are expected to have better growth in the coming years.

This research report on the APAC active pharmaceutical ingredients market has been segmented and sub-segmented into the following categories.

By Type of Manufacturing Process:

  • Captive Manufacturing
  • Contract Manufacturing

By Type of Synthesis:

  • Synthetic
  • Biotech

By API Formulation:

  • Generic API
  • Innovative API

By Application:

  • Cardiovascular Diseases
  • Oncology
  • Neurological Disorders
  • Orthopedic Disorders
  • Respiratory
  • Gastrointestinal Disorders
  • Urology
  • Others

By Molecule:

  • Large Molecule
  • Small Molecule

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the APAC regional market is predicted to dominate the global Active Pharmaceutical Ingredients Market during the forecast period due to the presence of emerging economies such as India and China that the world relies on the production of APIs at a lower cost is an advantage in this region.

The Chinese API market is most likely to contribute the most significant share of the APAC Active Pharmaceutical Ingredients market. Enhanced healthcare expenditures in this country and the adoption of advanced technology are expected to boost the market growth.

During the forecast period, the Indian market has been one of the fastest-growing regions in the APAC Active Pharmaceutical Ingredients Market. Increased research funding and engaged market participants are expected to drive market growth. Due to geopolitical circumstances and China's reliance on API goods, India has recently favored China to export API. The Active Pharmaceutical Ingredients market in India has grown significantly. Besides that, the Indian government has established plans and provided incentives to encourage the development of API.

The Japanese market is one of the promising regional markets in the APAC Active Pharmaceutical Ingredients Market and is predicted to grow substantially during the forecast period. Chronic diseases such as cardiovascular disease and chronic obstructive pulmonary disease are anticipated to push market growth.

KEY MARKET PLAYERS:

Notable market participants dominating the APAC active pharmaceutical ingredients profiled in this report are AbbVie Inc., AstraZeneca, Aurobindo Pharma Ltd., BASF, Bayer AG, Boehringer Ingelheim, Dr. Reddy's Laboratories, F. Hoffmann-La Roche, GlaxoSmithKline plc, Lonza Group, Lupin Limited, Merck & Co., Inc., Mylan NV, Novartis International AG, Pfizer Inc., Sanofi, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

  1. Introduction
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year and Forecast Periods
    4. General Study Assumptions
  2. Research Methodology
    1. Introduction
    2. Research Phases
        1. Secondary Research
        2. Primary Research
        3. Econometric Modelling
        4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Overview
    1. Executive Summary
    2. Key Inferences
    3. New Developments
  4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
    1. Market Drivers
    2. Market Restraints
    3. Key Challenges
    4. Current Opportunities in the Market
  5. Market Segmentation
    1. By Type of Manufacturing Process
      1. Captive Manufacturing
      2. Contract Manufacturing
      3. Y-o-Y Growth Analysis, By Manufacturing Process
      4. Market Attractiveness Analysis, By Manufacturing Process
      5. Market Share Analysis, By Manufacturing Process
    2. By Type of Synthesis
      1. Synthetic
      2. Biotech
      3. Y-o-Y Growth Analysis, By Type of Synthesis
      4. Market Attractiveness Analysis, By Type of Synthesis
      5. Market Share Analysis, By Type of Synthesis
    3. By API Formulation
      1. Generic API
      2. Innovative API
      3. Y-o-Y Growth Analysis, By API Formulation
      4. Market Attractiveness Analysis, By API Formulation
      5. Market Share Analysis, By API Formulation
    4. By Application
      1. Cardiovascular Diseases
      2. Oncology
      3. Neurological Disorders
      4. Orthopedic Disorders
      5. Respiratory
      6. Gastrointestinal Disorders
      7. Urology
      8. Others
      9. Y-o-Y Growth Analysis, By Application
      10.  Market Attractiveness Analysis, By Application
      11.  Market Share Analysis, By Application
    5. By Molecule
      1. Large Molecule
      2. Small Molecule
      3. Y-o-Y Growth Analysis, By Molecule
      4. Market Attractiveness Analysis, By Molecule
      5. Market Share Analysis, By Molecule
  6. Geographical Analysis
    1. Introduction    
      1. Regional Trends   
      2. Impact Analysis    
      3. Y-o-Y Growth Analysis        
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      4. Market Attractiveness Analysis      
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
      5.      Market Share Analysis   
        1. By Geographical Area
        2. By Product
        3. By Technology
        4. By Application
        5. By End-User
    2. Asia-Pacific
      1. Introduction
      2. India
      3. China
      4. Japan
      5. South Korea
      6. Australia
      7. Rest of APAC
  7. Strategic Analysis
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. Threat of New Entrants
      4. Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  8. Market Leaders' Analysis
    1. Sanofi
      1. Overview
      2. Product Analysis
      3. Strategic Evaluation and Operations
      4. Financial analysis
      5. Legal issues
      6. Recent Developments
      7. SWOT analysis
      8. Analyst View
    2. Bayer AG
    3. Pfizer Inc.
    4. F. Hoffmann-La Roche AG
    5. Abbott Laboratories
    6. Merck & Co., Inc.
    7. Boehringer Ingelheim GmbH
    8. Glaxosmithkline Plc (GSK)
    9. Novartis AG
    10. Eli Lilly and Company
    11. Teva Pharmaceutical Industries Ltd
  9. Competitive Landscape
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  10. Market Outlook and Investment Opportunities
  11. Appendix
    1. List of Tables
    2. List of Figures  
  • Global, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of type of manufacturing process, type of synthesis, api formulation, application, molecules along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market, which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. Asia Pacific Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  2. Asia Pacific Captive Manufacturing Market, By Region, From 2021 to 2026 (USD Million)
  3. Asia Pacific Contract Manufacturing Market, By Region, From 2021 to 2026 (USD Million)
  4. Asia Pacific Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  5. Asia Pacific Synthetic Market, By Region, From 2021 to 2026 (USD Million)
  6. Asia Pacific Biotech Market, By Region, From 2021 to 2026 (USD Million)
  7. Asia Pacific Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  8. Asia Pacific Generic API Market, By Region, From 2021 to 2026 (USD Million)
  9. Asia Pacific Innovative API Market, By Region, From 2021 to 2026 (USD Million)
  10. Asia Pacific Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  11. Asia Pacific Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Million)
  12. Asia Pacific Oncology Market, By Region, From 2021 to 2026 (USD Million)
  13. Asia Pacific Neurological Disorders Market, By Region, From 2021 to 2026 (USD Million)
  14. Asia Pacific Orthopaedic Disorders Market, By Region, From 2021 to 2026 (USD Million)
  15. Asia Pacific Respiratory Market, By Region, From 2021 to 2026 (USD Million)
  16. Asia Pacific Gastrointestinal Disorders Market, By Region, From 2021 to 2026 (USD Million)
  17. Asia Pacific Urology Market, By Region, From 2021 to 2026 (USD Million)
  18. Asia Pacific Others Market, By Region, From 2021 to 2026 (USD Million)
  19. Asia Pacific Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  20. Asia Pacific Large Molecule Market, By Region, From 2021 to 2026 (USD Million)
  21. Asia Pacific Small Molecule Market, By Region, From 2021 to 2026 (USD Million)
  22. Japan Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  23. Japan Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  24. Japan Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  25. Japan Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  26. Japan Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  27. China Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  28. China Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  29. China Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  30. China Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  31. China Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  32. India Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  33. India Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  34. India Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  35. India Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  36. India Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  37. Australia Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  38. Australia Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  39. Australia Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  40. Australia Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  41. Australia Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)
  42. South Korea Active Pharmaceutical Ingredients Market, By Type of Manufacturing process, From 2021 to 2026 (USD Million)
  43. South Korea Active Pharmaceutical Ingredients Market, By Type of Synthesis, From 2021 to 2026 (USD Million)
  44. South Korea Active Pharmaceutical Ingredients Market, By API Formulation, From 2021 to 2026 (USD Million)
  45. South Korea Active Pharmaceutical Ingredients Market, By Application, From 2021 to 2026 (USD Million)
  46. South Korea Active Pharmaceutical Ingredients Market, By Molecule, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample